<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="87938">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01960296</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 10-1067</org_study_id>
    <nct_id>NCT01960296</nct_id>
  </id_info>
  <brief_title>Does Continued Use of Clopidogrel Into Surgery Cause Increased Perioperative Bleeding?</brief_title>
  <official_title>Evaluation of Clopidogrel Use in Peri-Operative General Surgery Patients: A Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Doris Duke Charitable Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients who on taking clopidogrel are randomized to either continue clopidogrel into
      general surgery or discontinue clopidogrel 7 days before surgery. All patients resume
      clopidogrel after surgery. The investigators track the development of bleeding complications
      that may develop within 90 days of the surgery. Patients are medically cleared to be in
      either arm of the study by their cardiologist and surgeon. There is currently no evidence to
      support for or against the use continuation or discontinuation of clopidogrel prior to
      general surgery.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Perioperative Bleeding Complications</measure>
    <time_frame>up to 90 days post op</time_frame>
    <description>Development of perioperative bleeding complications, including need for blood transfusions, hematoma, and bleeding requiring re-admission or re-operation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Development of myocardial infarction or thrombosis</measure>
    <time_frame>up to 90 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Clopidogrel</condition>
  <arm_group>
    <arm_group_label>Clopidogrel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Continue home dose of clopidogrel into surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Discontinue</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Discontinue home dose of clopidogrel one week before surgery. Resume after surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>Continue home dose of clopidogrel into surgery</description>
    <arm_group_label>Clopidogrel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Discontinue Clopidogrel</intervention_name>
    <description>Discontinue home dose of clopidogrel one week before surgery. Resume after surgery.</description>
    <arm_group_label>Discontinue</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  taking clopidogrel

          -  undergoing general surgery

          -  cleared by both cardiologist and surgery for randomized arm

        Exclusion Criteria:

          -  previous history of bleeding complications/bleeding disposition

          -  no capacity to consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Celia M Divino, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <lastchanged_date>November 4, 2015</lastchanged_date>
  <firstreceived_date>October 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>clopidogrel</keyword>
  <keyword>general surgery</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
